華潤醫藥(03320.HK)旗下華潤雙鶴與真實生物就口服新冠藥進行戰略合作
華潤醫藥(03320.HK)表示,河南真實生物抑制新冠病毒RNA依賴的RNA聚合(酉每)的阿茲夫定片,獲國家藥監局應急附條件批准用於治療普通型新冠肺炎成年患者。阿茲夫定片是中國自主研發的口服小分子藥物。
而華潤醫藥旗下子公司華潤雙鶴(600062.SH)早前已與真實生物在北京簽署《戰略合作協議》及《阿茲夫定片委託加工生產框架協議》,受託加工生產真實生物的阿茲夫定片產品。雙方將在產品研發、生產、經銷以及與經銷直接相關的多個領域拓展合作。針對阿茲夫定產品委託加工相關事宜。
目前,華潤雙鶴已就該藥品生產獲得藥品生產許可證C證,具備受託加工該產品的生產能力和品質保證能力。真實生物已向相關部門提交有關「增加生產地址」的藥品生產許可證B證核發申請。(eku)~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.